{
  "nctId": "NCT03931109",
  "briefTitle": "Circulating miRNA in Primary Hyperparathyroidism",
  "officialTitle": "Circulating microRNA Signatures in Primary Hyperparathyroidism",
  "protocolDocument": {
    "nctId": "NCT03931109",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-08-06",
    "uploadDate": "2019-04-23T15:59",
    "size": 300383,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03931109/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 96,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-09-07",
    "completionDate": "2024-07-01",
    "primaryCompletionDate": "2024-07-01",
    "firstSubmitDate": "2019-04-15",
    "firstPostDate": "2019-04-30"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* post menopausal\n* has had DXA scan\n* has 24 hr Urine Calcium\n* Elevated serum calcium\n* Vitamin D above 20 ng/ml\n* capable of giving informed consent\n* female\n* indication for biochemical primary hyperparathyroidism or an indication for partial or total thyroidectomy\n\nExclusion Criteria:\n\n* history of ESRD on dialysis or renal osteodystrophy\n* prior parathyroidectomy\n* hyper or hypothyroid by TSH\n* currently taking steroids or has been on steroids for more than 7 days in the last two years\n* estrogen therapy within the last two years\n* bisphosphonate therapy within the last two years\n* diagnosis of Cushing's disease or Cushing's syndrome\n* taking biotin within 24 hours of blood draw",
    "healthyVolunteers": false,
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "maximumAge": "100 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "circulating microRNAs in primary hyperparathyroidism patients",
        "description": "Serum miRNA levels",
        "timeFrame": "2019-2021"
      },
      {
        "measure": "serum miRNA after parathyroidectomy",
        "description": "clinical markers of bone remodeling, including serum levels of bone-specific alkaline phosphatase, osteocalcin, P1NP, CTX, calcium, phosphate, Vitamin D metabolites, and PTH; urine calcium; and DXA scan",
        "timeFrame": "2019-2021"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:03.607Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}